Literature DB >> 33674359

Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.

Jaclyn N Highland1, Panos Zanos1, Lace M Riggs1, Polymnia Georgiou1, Sarah M Clark1, Patrick J Morris1, Ruin Moaddel1, Craig J Thomas1, Carlos A Zarate1, Edna F R Pereira1, Todd D Gould2.   

Abstract

Hydroxynorketamines (HNKs) are formed in vivo after (R,S)-ketamine (ketamine) administration. The 12 HNK stereoisomers are distinguished by the position of cyclohexyl ring hydroxylation (at the 4, 5, or 6 position) and their unique stereochemistry at two stereocenters. Although HNKs were initially classified as inactive metabolites because of their lack of anesthetic effects, more recent studies have begun to reveal their biologic activities. In particular, (2R,6R)- and (2S 6)-HNK exert antidepressant-relevant behavioral and physiologic effects in preclinical models, which led to a rapid increase in studies seeking to clarify the mechanisms by which HNKs exert their pharmacological effects. To date, the majority of HNK research has focused on the actions of (2R,6R)-HNK because of its robust behavioral actions in tests of antidepressant effectiveness and its limited adverse effects. This review describes HNK pharmacokinetics and pharmacodynamics, as well as the putative cellular, molecular, and synaptic mechanisms thought to underlie their behavioral effects, both following their metabolism from ketamine and after direct administration in preclinical studies. Converging preclinical evidence indicates that HNKs modulate glutamatergic neurotransmission and downstream signaling pathways in several brain regions, including the hippocampus and prefrontal cortex. Effects on other neurotransmitter systems, as well as possible effects on neurotrophic and inflammatory processes, and energy metabolism, are also discussed. Additionally, the behavioral effects of HNKs and possible therapeutic applications are described, including the treatment of unipolar and bipolar depression, post-traumatic stress disorder, chronic pain, neuroinflammation, and other anti-inflammatory and analgesic uses. SIGNIFICANCE STATEMENT: Preclinical studies indicate that hydroxynorketamines (HNKs) exert antidepressant-relevant behavioral actions and may also have analgesic, anti-inflammatory, and other physiological effects that are relevant for the treatment of a variety of human diseases. This review details the pharmacokinetics and pharmacodynamics of the HNKs, as well as their behavioral actions, putative mechanisms of action, and potential therapeutic applications. U.S. Government work not protected by U.S. copyright.

Entities:  

Year:  2021        PMID: 33674359      PMCID: PMC7938660          DOI: 10.1124/pharmrev.120.000149

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  124 in total

1.  Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine.

Authors:  J F MacDonald; Z Miljkovic; P Pennefather
Journal:  J Neurophysiol       Date:  1987-08       Impact factor: 2.714

2.  Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects.

Authors:  Thu Ha Pham; Céline Defaix; Xiaoming Xu; Shi-Xian Deng; Nicolas Fabresse; Jean-Claude Alvarez; Donald W Landry; Rebecca A Brachman; Christine A Denny; Alain M Gardier
Journal:  Biol Psychiatry       Date:  2017-10-26       Impact factor: 13.382

Review 3.  A REVIEW OF KETAMINE ABUSE AND DIVERSION.

Authors:  Sean Sassano-Higgins; Dave Baron; Grace Juarez; Neevon Esmaili; Mark Gold
Journal:  Depress Anxiety       Date:  2016-06-22       Impact factor: 6.505

4.  What role does the (2R,6R)-hydronorketamine metabolite play in the antidepressant-like and abuse-related effects of (R)-ketamine?

Authors:  Todd M Hillhouse; Remington Rice; Joseph H Porter
Journal:  Br J Pharmacol       Date:  2019-08-17       Impact factor: 8.739

Review 5.  Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system.

Authors:  D D Schoepp
Journal:  J Pharmacol Exp Ther       Date:  2001-10       Impact factor: 4.030

6.  Effect of the α2 -receptor agonists medetomidine, detomidine, xylazine, and romifidine on the ketamine metabolism in equines assessed with enantioselective capillary electrophoresis.

Authors:  Friederike A Sandbaumhüter; Regula Theurillat; Regula Bettschart-Wolfensberger; Wolfgang Thormann
Journal:  Electrophoresis       Date:  2017-03-20       Impact factor: 3.535

7.  Effects of optical isomers of ketamine on excitation of cat and rat spinal neurones by amino acids and acetylcholine.

Authors:  D Lodge; N A Anis; N R Burton
Journal:  Neurosci Lett       Date:  1982-04-26       Impact factor: 3.046

8.  Metabolism of ketamine stereoisomers by human liver microsomes.

Authors:  E D Kharasch; R Labroo
Journal:  Anesthesiology       Date:  1992-12       Impact factor: 7.892

9.  Studies on the biotransformation of ketamine. 1-Identification of metabolites produced in vitro from rat liver microsomal preparations.

Authors:  J D Adams; T A Baillie; A J Trevor; N Castagnoli
Journal:  Biomed Mass Spectrom       Date:  1981-11

Review 10.  Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.

Authors:  Todd D Gould; Carlos A Zarate; Scott M Thompson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-10-08       Impact factor: 13.820

View more
  16 in total

1.  Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis.

Authors:  Gustavo C Medeiros; Todd D Gould; William L Prueitt; Julie Nanavati; Michael F Grunebaum; Nuri B Farber; Balwinder Singh; Sudhakar Selvaraj; Rodrigo Machado-Vieira; Eric D Achtyes; Sagar V Parikh; Mark A Frye; Carlos A Zarate; Fernando S Goes
Journal:  Mol Psychiatry       Date:  2022-06-27       Impact factor: 15.992

2.  Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search.

Authors:  Jordi Bonaventura; Juan L Gomez; Meghan L Carlton; Sherry Lam; Marta Sanchez-Soto; Patrick J Morris; Ruin Moaddel; Hye Jin Kang; Panos Zanos; Todd D Gould; Craig J Thomas; David R Sibley; Carlos A Zarate; Michael Michaelides
Journal:  Mol Psychiatry       Date:  2022-06-29       Impact factor: 15.992

Review 3.  Mechanisms of ketamine and its metabolites as antidepressants.

Authors:  Evan M Hess; Lace M Riggs; Michael Michaelides; Todd D Gould
Journal:  Biochem Pharmacol       Date:  2021-12-27       Impact factor: 5.858

Review 4.  [Rapid-acting antidepressants-neurobiological mechanisms of action].

Authors:  Peter Gass; Andrei N Vasilescu; Dragos Inta
Journal:  Nervenarzt       Date:  2021-11-11       Impact factor: 1.214

5.  Antinociceptive and Analgesic Effects of (2R,6R)-Hydroxynorketamine.

Authors:  Jonathan G Yost; Hildegard A Wulf; Caroline A Browne; Irwin Lucki
Journal:  J Pharmacol Exp Ther       Date:  2022-07-02       Impact factor: 4.402

6.  Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series.

Authors:  Hewa Artin; Sean Bentley; Eamonn Mehaffey; Fred X Liu; Kevin Sojourner; Andrew W Bismark; David Printz; Ellen E Lee; Brian Martis; Sharon De Peralta; Dewleen G Baker; Jyoti Mishra; Dhakshin Ramanathan
Journal:  EClinicalMedicine       Date:  2022-05-06

Review 7.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

Review 8.  Ketamine and the Future of Rapid-Acting Antidepressants.

Authors:  Lace M Riggs; Todd D Gould
Journal:  Annu Rev Clin Psychol       Date:  2021-02-09       Impact factor: 18.561

9.  A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801.

Authors:  Patrick J Morris; Richard D Burke; Alok K Sharma; Daniel C Lynch; Leslie E Lemke-Boutcher; Shiny Mathew; Ikram Elayan; Deepa B Rao; Todd D Gould; Carlos A Zarate; Panos Zanos; Ruin Moaddel; Craig J Thomas
Journal:  Neurotoxicol Teratol       Date:  2021-05-01       Impact factor: 4.071

10.  A new molecular target for antidepressants.

Authors:  Sarah Ateaque; Yves-Alain Barde
Journal:  Cell Res       Date:  2021-05       Impact factor: 46.297

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.